Ebit 更改
Agenus USD 14.4M 19.26M 2025-12
Amgen USD 3.83B 130M 2026-03
Anika Therapeutics USD 646K 3.88M 2025-12
Arrowhead Research USD 40.81M 17.01M 2025-12
AstraZeneca USD 7.11B 4.14B 2026-03
BioMarin Pharmaceutical USD 129.65M 68.74M 2026-03
Bristol-Myers Squibb USD 3.56B 90M 2026-03
Celldex Therapeutics USD -87.15M 13.54M 2025-12
Daiichi Sankyo JPY 89.54B 42.01B 2025-12
Eli Lilly USD 9.78B 792M 2026-03
Halozyme Therapeutics USD -88.41M 306.33M 2025-12
Heron Therapeutics USD 38K 3.83M 2025-12
Intrexon USD -26.3M 2.91M 2024-06
Ionis Pharmaceuticals USD -118M 97M 2026-03
Karyopharm Therapeutics USD -17.84M 8.44M 2025-12
Ligand Pharmaceuticals USD 158.89M 115.32M 2025-09
MacroGenics USD -12.1M 32.26M 2025-12
Neurocrine Biosciences USD 227.9M 11.4M 2025-12
Pfizer USD 4.65B 71M 2025-12
Regeneron Pharmaceuticals USD 744.8M 153.8M 2026-03
Rigel Pharmaceuticals USD 447K 1.52M 2024-06
Ultragenyx Pharmaceutical USD -114M 56.89M 2025-12
Veracyte USD 24.63M 1.52M 2025-12